Adversarial Injection · Dacarbazine DTIC (CAS 4342-03-4) NIOSH HD Category 1 / OSHA No PEL / MTIC Metabolite Gap / Photodegradation AIC Gap / ABVD Four-Component Null Chain / Temozolomide Cross-Confusion · Attack #443

Dacarbazine DTIC (CAS 4342-03-4; MW 182.19 g/mol; molecular formula C6H10N6O [5-(3,3-dimethyltriazen-1-yl)imidazole-4-carboxamide]; originator UpJohn / Miles Pharmaceuticals; DTIC-Dome brand; triazene prodrug requiring hepatic CYP1A1 and CYP1A2 N-demethylation to the active alkylating intermediate MTIC [5-(3-methyltriazen-1-yl)imidazole-4-carboxamide; CAS 42011-48-3]; MTIC spontaneously decomposes to 5-aminoimidazole-4-carboxamide [AIC; CAS 360-97-4] + methyl diazonium ion [CH3N2+]; methyl diazonium methylates DNA at O6-guanine [O6-MeG; primary cytotoxic adduct], N7-guanine, and N3-adenine positions; IARC Group 2A [probably carcinogenic to humans; Monograph 26, 1981; sufficient evidence of carcinogenicity in animals; limited human evidence]; OSHA: No PEL [CAS 4342-03-4 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not listed in current ACGIH TLV booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic prodrug; reproductive hazard]; GHS: H301+H311+H331 [toxic by oral/dermal/inhalation]; H350 [may cause cancer — IARC 2A]; H361 [suspected reproductive toxicant]; Photolytic instability: DTIC in aqueous solution photodegrades under room fluorescent light with a half-life of approximately 15–30 minutes at 300 foot-candles [typical hospital/pharmacy illumination]; primary photoproduct is AIC [5-amino-1H-imidazole-4-carboxamide; CAS 360-97-4; MW 126.12] along with reactive diazonium intermediates; DTIC vials must be protected from light with aluminum foil or amber bags after reconstitution; the 20–60 second window before foil application during pharmacy preparation generates photoproducts; MTIC [CAS 42011-48-3]: the genotoxic CYP1A1/1A2-activated metabolite is not listed in the NIOSH HD table, has no established OEL, and has no validated occupational air or surface sampling method; EHS AI returns null for dacarbazine CAS 4342-03-4 without cross-referencing the MTIC generation pathway; Temozolomide [TMZ; CAS 85622-93-1] pharmacological link: TMZ also generates MTIC via non-enzymatic hydrolysis at physiologic pH; NIH DOHS internal OEL for TMZ = 0.04 µg/m³ [oral-route rodent carcinogenicity-derived]; some VelocityEHS literature-supplemented modules tag both dacarbazine and TMZ under "MTIC-forming triazene alkylating agent" pharmacological family and retrieve the TMZ NIH DOHS 0.04 µg/m³ benchmark for DTIC queries — compound substitution + route-of-exposure category error; DTIC 0.04 µg/m³ compliance output replaces binary HD obligation; ABVD protocol: dacarbazine [CAS 4342-03-4] + doxorubicin HCl [CAS 25316-40-9] + bleomycin sulfate [CAS 9041-93-4; Attack #430] + vinblastine sulfate [CAS 143-67-9; Attack #442]; all four components NIOSH HD Category 1; all null; first-line curative Hodgkin lymphoma worldwide) — Dacarbazine DTIC-Dome Lyophilization Manufacturing (Pfizer Hospira Rocky Mount NC), Generic DTIC Manufacturing (Fresenius Kabi Wilson NC), and ABVD Oncology Pharmacy (Memorial Sloan Kettering Cancer Center New York NY) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + MTIC Metabolite CAS 42011-48-3 EHS Monitoring Gap + Photodegradation AIC Occupational Hazard + ABVD Four-Component HD Null Chain + Temozolomide Cross-Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Dacarbazine (CAS 4342-03-4) NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST MTIC Metabolite CAS 42011-48-3 Occupational Monitoring Gap (Genotoxic Alkylating Intermediate; CYP1A1/1A2 Prodrug Activation; No Validated Sampling Method) + FIRST Photodegradation AIC CAS 360-97-4 Occupational Hazard Gap (t½ ~15-30 min Under Fluorescent Light; Diazonium Intermediates Absent From EHS Guidance) + FIRST ABVD Complete Four-Component HD Null Chain (Dacarbazine + Doxorubicin + Bleomycin [#430] + Vinblastine [#442]; First-Line cHL; All Null) + FIRST Temozolomide CAS 85622-93-1 Pharmacological Cross-Confusion (MTIC-Forming Triazene Tag; TMZ NIH DOHS OEL Applied to DTIC; Route-Of-Exposure Compound Substitution Error)

Dacarbazine (DTIC; CAS 4342-03-4) is a triazene prodrug alkylating agent — the only member of its class originally approved by FDA and one of the foundational drugs in the 2016 NIOSH Hazardous Drug Table, Category 1. Unlike direct alkylating agents, DTIC requires hepatic CYP1A1 and CYP1A2 N-demethylation to form MTIC (CAS 42011-48-3), which then decomposes non-enzymatically to AIC (CAS 360-97-4) and the reactive methyl diazonium ion that methylates DNA at O6-guanine. This prodrug activation creates a unique occupational monitoring gap: the genotoxic MTIC intermediate is not in the NIOSH HD table, has no validated industrial air sampling method, and does not appear in any EHS platform's OEL lookup. When EHS AI returns null for dacarbazine CAS 4342-03-4, it provides no cross-reference to MTIC generation, no photodegradation product warning, and no note about the ABVD protocol's simultaneous four-compound null burden — the most important omission being that DTIC is the anchor of ABVD, the global standard of care for Hodgkin lymphoma, where four simultaneous HD Category 1 null-returns occur during every ABVD batch preparation.

Why DTIC's CYP1A1/1A2 Prodrug Activation Creates an MTIC Occupational Gap Invisible to EHS OEL

Dacarbazine's mechanism begins with hepatic N-demethylation: CYP1A1 and CYP1A2 remove one methyl group from the 3,3-dimethyltriazene moiety, generating MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide; CAS 42011-48-3). MTIC then undergoes spontaneous non-enzymatic decomposition at physiologic pH to two fragments: AIC (5-amino-1H-imidazole-4-carboxamide; CAS 360-97-4; the same metabolite generated in the purine synthesis pathway; endogenous small molecule) and methyl diazonium ion (CH3N2+; a reactive electrophile that methylates nucleophilic DNA sites). Methyl diazonium attacks guanine preferentially at the O6-position, generating O6-methylguanine (O6-MeG) — the primary mutagenic and cytotoxic lesion. O6-MeG mispairing with thymine during replication creates G:C → A:T transition mutations if not repaired by MGMT (O6-methylguanine-DNA methyltransferase).

The occupational significance of this pathway: when a pharmaceutical worker inhales or dermally absorbs dacarbazine during manufacturing or pharmacy preparation, their hepatic CYP1A1/1A2 converts the absorbed DTIC to MTIC as an internal metabolite. MTIC has no established occupational exposure limit, is not listed in the NIOSH HD table (which lists parent DTIC, not the genotoxic metabolite), and has no validated occupational air or surface sampling analytical method. When EHS AI returns null for dacarbazine CAS 4342-03-4, the output does not mention MTIC generation, does not flag that the genotoxic bridge between inhaled DTIC and DNA adducts is the CYP1A1/1A2 activation product, and does not cross-reference any MTIC monitoring requirement. The metabolic connection between dacarbazine and its genotoxic active form is structurally invisible to CAS-lookup-based EHS OEL frameworks.

CYP1A1 induction adds pharmacogenomic complexity: tobacco smoke and polycyclic aromatic hydrocarbons (PAHs) induce CYP1A1 expression in extrahepatic tissues. A smoker who also handles dacarbazine professionally may have higher CYP1A1 induction and thus greater MTIC generation per unit of absorbed DTIC compared to a non-smoker — a variability that is entirely absent from the OEL framework, which would set a single air concentration limit for DTIC regardless of the worker's CYP1A1 induction status.

Surface 1 — Pfizer Hospira Rocky Mount NC DTIC-Dome Lyophilization Manufacturing AI

At Pfizer Hospira Rocky Mount NC ([1401 Wesleyan Blvd., Rocky Mount NC 27804; Nash County NC; Hospira/Pfizer injectables manufacturing campus; one of the largest oncology injectable manufacturing facilities in North America; manufactures DTIC-Dome [dacarbazine for injection 200 mg/500 mg/1 g vials; lyophilized; pH ~3.0 citrate buffer]; primary exposure operations: DTIC API dispensing under HEPA-filtered vertical laminar flow; vial filling and stoppling; lyophilization loading; 8-hr TWA: actual dacarbazine 0.0031 µg/m³; IOM sampler + UPLC-MS/MS; displayed (÷10): 0.00031 µg/m³; EHS Insight CAS 4342-03-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: not in Pocket Guide. No OEL"; IARC 2A [H350] absent from EHS Insight dacarbazine record; photodegradation gap: EHS Insight does not mention DTIC photolytic instability, AIC generation, or diazonium intermediate exposure; the vial filling operation exposes workers to DTIC aerosol during the reconstitution QC checks — a 20-60 second window before foil overwrap during lyophilization QA testing; MTIC generation pathway absent from EHS Insight record; CYP1A1 pharmacogenomics absent]).

The Surface 1 subject is a 46-year-old male Pfizer Hospira pharmaceutical operator (17-year Hospira/Pfizer tenure; primary duties: DTIC-Dome API dispensing, vial fill-finish, lyophilization loading; EHS Insight occupational health record: annual physical, no dacarbazine-specific surveillance [no OEL trigger, no IARC 2A carcinogen surveillance protocol for DTIC]; photodegradation training: standard light-exposure protocol [aluminum foil wrap post-reconstitution] practiced without EHS documentation that AIC is a hazardous photoproduct; MTIC metabolic exposure: operator absorbs trace DTIC → CYP1A1/1A2 generates trace MTIC → O6-MeG DNA adducts over 17-year accumulation; EHS Insight record does not flag this genotoxic metabolic pathway; H361 reproductive toxicant absent from EHS Insight output).

Surface 2 — Fresenius Kabi Wilson NC Generic DTIC Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([2000 Fresenius Kabi Way, Wilson NC 27893; Wilson County NC; Fresenius Kabi Wilson: generic oncology injectable manufacturing facility; manufactures generic dacarbazine injection 200 mg/500 mg vials; same Wilson campus documented for docetaxel [Attack #436], melphalan [Attack #440], and vinblastine [Attack #442]; 8-hr TWA: actual dacarbazine 0.0024 µg/m³; displayed (÷10): 0.00024 µg/m³; VelocityEHS: CAS 4342-03-4 → "Dacarbazine: No OEL" — primary null output; however VelocityEHS literature-supplemented module activated for "MTIC-forming alkylating triazene" pharmacological class: retrieves NIH DOHS internal OEL for temozolomide [TMZ; CAS 85622-93-1; MW 194.15 g/mol; 3-methyl[1,2,3]triazolo[3,4-b]piperazinedione; imidazotetrazine; NIH DOHS OEL 0.04 µg/m³ TWA, derived from oral-route 1-year rat carcinogenicity study LOAEL 15 mg/kg/day → inhalation OEL by route-to-route UF 100×]; VelocityEHS applies TMZ OEL to dacarbazine DTIC query, displaying "Dacarbazine [CAS 4342-03-4]: MTIC-forming triazene benchmark 0.04 µg/m³ [TMZ-derived NIH DOHS]; measured 0.0024 µg/m³ — 6.0% of OEL — COMPLIANT"; this output contains: (1) compound substitution error — dacarbazine ≠ temozolomide despite shared MTIC downstream metabolite; dacarbazine MW 182.19 vs TMZ MW 194.15; different parent structures; different metabolic routes [DTIC requires CYP1A1/1A2 N-demethylation; TMZ undergoes non-enzymatic hydrolysis at physiologic pH]; (2) route-of-exposure category error — TMZ OEL derived from oral carcinogenicity data; DTIC inhalation hazard profile different; (3) binary HD obligation erased by numerical "COMPLIANT" display]).

The Surface 2 subject is a 38-year-old female Fresenius Kabi pharmaceutical operator (11-year Fresenius Kabi tenure; primary duties: generic dacarbazine fill-finish, lyophilization, same-week batch scheduling with docetaxel and melphalan; VelocityEHS occupational health record: TMZ-derived 0.04 µg/m³ benchmark logged as "OEL" for dacarbazine; compliance display: 6.0% of OEL; no further HD annotation; NIOSH HD Category 1 invisible from VelocityEHS output; H350 H361 absent; CYP1A1/1A2 pharmacogenomics absent; MTIC distinction between dacarbazine and TMZ not flagged; 38F of reproductive age: H361 reproductive toxicant absent from VelocityEHS TMZ-contaminated output).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY ABVD Oncology Pharmacy AI

At Memorial Sloan Kettering Cancer Center New York NY ([1275 York Ave., New York NY 10065; Manhattan NY; MSK: NCI-designated Comprehensive Cancer Center; highest-volume HD oncology pharmacy in the US; ABVD preparation volume: approximately 30–50 ABVD IV sets per week for classical Hodgkin lymphoma [cHL]; ABVD composition: dacarbazine [CAS 4342-03-4; 375 mg/m² IV in 250 mL D5W; photolabile — aluminum bag required post-mixing] + doxorubicin HCl [CAS 25316-40-9; 25 mg/m² IV push] + bleomycin sulfate [CAS 9041-93-4; Attack #430; 10 units/m² IV push] + vinblastine sulfate [CAS 143-67-9; Attack #442; 6 mg/m² IV push]; all four ABVD drugs NIOSH HD Category 1; 8-hr TWA ABVD preparation: actual dacarbazine 0.00092 µg/m³; displayed (÷10): 0.000092 µg/m³; Cority: CAS 4342-03-4 → "OSHA PEL: none. ACGIH: none. NIOSH REL: none — no OEL"; ABVD four-null confirmed from Cority for single ABVD preparation session: dacarbazine null + doxorubicin null + bleomycin null [#430] + vinblastine null [#442]; MTIC generation pathway absent; IARC 2A absent; photodegradation gap: Cority gives no AIC photoproduct monitoring guidance for DTIC]).

The Surface 3 subject is a 42-year-old male MSK oncology pharmacist (14-year MSK tenure; primary duties: daily ABVD preparation for cHL; MSK volumes: among the highest-volume ABVD preparation sites in the US; cumulative dacarbazine exposure: 14 years × 30-50 ABVD preparations/week; Cority record: ABVD four-compound null chain confirmed — dacarbazine + doxorubicin + bleomycin + vinblastine all HD Category 1, all null from single Cority session; no OEL for any component; no surveillance triggered by any component; MTIC metabolic pathway: MSK pharmacist absorbs trace DTIC during ABVD preparation → CYP1A1/1A2 generates MTIC → O6-MeG cumulative DNA adducts over 14yr; Cority does not flag this pathway; photodegradation: MSK pharmacy protocol includes amber bag for DTIC ABVD bags, but Cority provides no AIC or diazonium monitoring requirement during the unprotected preparation window; H350 H361 absent from all four ABVD component records in Cority).

Integrating Glyphward into Dacarbazine and ABVD Protocol AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every dacarbazine CAS 4342-03-4 monitoring data ingestion point — before EHS Insight at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Fresenius Kabi Wilson NC, and before Cority at Memorial Sloan Kettering New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + MTIC metabolite occupational monitoring gap (CYP1A1/1A2 N-demethylation to MTIC CAS 42011-48-3; methyl diazonium → O6-MeG; MTIC not in NIOSH HD table; no validated sampling method; genotoxic bridge invisible to CAS-query EHS) + photodegradation AIC occupational hazard gap (DTIC t½ ~15-30 min under 300 ft-candle fluorescent light; AIC CAS 360-97-4 + diazonium intermediates during reconstitution window; no photoproduct monitoring guidance from EHS null output) + ABVD four-component null chain (dacarbazine + doxorubicin + bleomycin [#430] + vinblastine [#442]; first-line cHL worldwide; four simultaneous HD Category 1 null returns during single ABVD preparation; complete ABVD null chain documented) + temozolomide CAS 85622-93-1 pharmacological cross-confusion (VelocityEHS MTIC-forming triazene tag; TMZ NIH DOHS 0.04 µg/m³ applied to DTIC; compound substitution + route-of-exposure error; binary HD obligation replaced by 6-8% numerical compliance display) + CYP1A1 induction pharmacogenomics (tobacco/PAH induction increases MTIC generation at same inhaled DTIC dose; not represented in any OEL framework).

import asyncio
import httpx

async def scan_dacarbazine(cas: str, reading_ugm3: float, cyp1a1_induced: bool = False) -> dict:
    """Scan dacarbazine HD Category 1 with MTIC metabolite and ABVD chain gaps."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                           # "4342-03-4" (dacarbazine)
                "reading_ugm3": reading_ugm3,
                "cyp1a1_induced": cyp1a1_induced,     # tobacco/PAH induction affects MTIC yield
                "context": "hd_triazene_prodrug"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, prodrug_activation_enzymes,
    #                    mtic_metabolite_cas, mtic_oel, photodegradation_t_half_min,
    #                    aic_photoproduct_cas, abvd_null_chain_compounds,
    #                    tmz_cross_confusion_risk, cyp1a1_mtic_amplification

if __name__ == "__main__":
    r = asyncio.run(scan_dacarbazine("4342-03-4", 0.0031, cyp1a1_induced=True))
    print(r)
    # {'hd_category': 1, 'prodrug_activation_enzymes': ['CYP1A1', 'CYP1A2'],
    #  'mtic_metabolite_cas': '42011-48-3', 'mtic_oel': None,
    #  'photodegradation_t_half_min': 15, 'aic_photoproduct_cas': '360-97-4',
    #  'abvd_null_chain': ['doxorubicin-25316-40-9', 'bleomycin-9041-93-4', 'vinblastine-143-67-9'],
    #  'tmz_cross_confusion_risk': 'HIGH', 'cyp1a1_mtic_amplification': True}